Skip to Content
Morningstar

Spruce Biosciences Inc Ordinary Shares SPRB

Morningstar Rating
Unlock
Stock XNAS Rating as of
$0.70 0.00 (0.14%)
View Full Chart
As of Delayed Price Post-Trading: $0.70 0.00
Unlock our analysis with Morningstar Investor
Start Free Trial

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
SPRB is trading at a 62% discount.
Price
$0.69
Fair Value
$2.50
Uncertainty
Extreme
1-Star Price
$67.54
5-Star Price
$6.17
Economic Moat
Zmqk
Capital Allocation
—
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SPRB is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$0.70
Day Range
$0.70–0.71
52-Week Range
$0.67–5.95
Bid/Ask
$0.70 / $0.70
Market Cap
$28.81 Mil
Volume/Avg
210,515 / 1.4 Mil

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
2.68
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
29
Website
https://www.sprucebiosciences.com

Comparables

Valuation

View More
Metric
SPRB
CBAY
DYN
Price/Earnings (Normalized)
 ———
Price/Book Value
 0.3812.6515.95
Price/Sales
 2.68111.01—
Price/Cash Flow
 ———
Price/Earnings
SPRB
CBAY
DYN

Financial Strength

Metric
SPRB
CBAY
DYN
Quick Ratio
 3.9410.702.41
Current Ratio
 4.1810.962.53
Interest Coverage
 −107.65−5.27—
Quick Ratio
SPRB
CBAY
DYN

Profitability

Metric
SPRB
CBAY
DYN
Return on Assets (Normalized)
 −38.14%−30.06%−88.69%
Return on Equity (Normalized)
 −49.77%−51.97%−114.25%
Return on Invested Capital (Normalized)
 −51.22%−30.87%−102.56%
Return on Assets
SPRB
CBAY
DYN
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRZdclpjthXkch$554.7 Bil
VRTX
Vertex Pharmaceuticals IncFgfmjzqsMgyzyb$103.6 Bil
REGN
Regeneron Pharmaceuticals IncGdsnhbglkKjqmlnz$97.8 Bil
MRNA
Moderna IncZjbpcdkkRjxnt$38.8 Bil
ARGX
argenx SE ADRBysncjzjTslw$22.0 Bil
BNTX
BioNTech SE ADRVcryfjzZkrs$21.2 Bil
ALNY
Alnylam Pharmaceuticals IncNbtwzwlqvYfmlrw$18.2 Bil
BMRN
Biomarin Pharmaceutical IncWyydbywqMhtcjj$17.3 Bil
RPRX
Royalty Pharma PLC Class ASsfygvvdzkXdltxd$12.5 Bil
INCY
Incyte CorpGbsydmvnyKvrhft$11.5 Bil

Sponsor Center